-Celia A Schiffer Researcher Activity Profile

Research Author Detailed Information 

Celia A Schiffer Publication Rate By Year

Celia A Schiffer has published 1 paper(s) in 2004, 3 paper(s) in 2006, 8 paper(s) in 2007, 6 paper(s) in 2008, for a total of 18 research publications in total.

Celia A Ca Schiffer Author Information

LAST NAME: schiffer

FIRST NAME: Celia A

INITIALS: ca

AFFILIATION:

Papers

Celia A Schiffer's Publication Record

1. Competition between Ski and CREB-binding protein for binding to Smad proteins in transforming growth factor-beta signaling. Year Published: 2007
Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA. Weijun.Chen@umassmed.edu
2. RecA dimers serve as a functional unit for assembly of active nucleoprotein filaments. Year Published: 2006
Department of Biochemistry and Molecular Pharmacology, Aaron Lazare Research Building, 364 Plantation Street, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.
3. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands. Year Published: 2006
Chemical Biology Program, Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.
4. N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. Year Published: 2007
Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California 94305, USA.
5. Hydrophobic sliding: a possible mechanism for drug resistance in human immunodeficiency virus type 1 protease. Year Published: 2007
Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA.
6. Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres. Year Published: 2007
Chemical Biology Program and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.
7. Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity. Year Published: 2007
Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA.
8. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Year Published: 2007
9. World health organization and international prognostic scoring system: the limitations of current classification systems in assessing prognosis and determining appropriate therapy in myelodysplastic syndromes. Year Published: 2008
Division of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI.
10. Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease. Year Published: 2008
Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
11. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Year Published: 2007
Rush University Medical Center, Chicago, IL, USA.
12. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-{alpha} treatment. Year Published: 2008
13. Marrow failure. Year Published: 2004
14. Clinical issues in the management of patients with myelodysplasia. Year Published: 2006
Barbara Ann Karmanos Cancer Institute, Wayne State University (SOM), 4100 John R. Street, 4HW-CRC, Detroit MI 48201, USA. schiffer@karmanos.org
15. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Year Published: 2007
Rush University Medical Center, Chicago, IL, USA.
16. World Health Organization and international prognostic scoring system: the limitations of current classification systems in assessing prognosis and determining appropriate therapy in myelodysplastic syndromes. Year Published: 2008
Division of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA. Schiffer@karmanos.org
17. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Year Published: 2008
Medizinische Fakultaet Mannheim, University of Heidelberg, Mannheim, Germany.
18. Monitoring minimal residual disease in patients with chronic myeloid leukemia after treatment with tyrosine kinase inhibitors. Year Published: 2008
Division of Hematology/Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.